Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
2012 · New England Journal of Medicine · 466 citations
https://doi.org/10.1056/nejmoa1111097
H
Harry D. Bear
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
333
Papers
17.6K
Citations
52
h-index
130
i10-index
Harry D. Bear is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Breast Cancer Treatment Studies & Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers. The author has an h-index of 52, co-authored 284 publications.
ORCID: 0000-0002-7632-9019Papers by this author
worksLapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013 · The Lancet Oncology · 384 citations
https://doi.org/10.1016/s1470-2045(13)70411-x
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
2021 · Journal of Clinical Oncology · 315 citations
https://doi.org/10.1200/jco.20.03639
Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function
2009 · Journal of Translational Medicine · 166 citations
https://doi.org/10.1186/1479-5876-7-89
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
2013 · Journal of Translational Medicine · 104 citations
https://doi.org/10.1186/1479-5876-11-145
Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells
2008 · Cancer Immunology Immunotherapy · 60 citations
https://doi.org/10.1007/s00262-008-0609-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat